Update shared on07 Aug 2025
Fair value Decreased 19%Evolus’s valuation outlook is slightly more cautious due to a higher discount rate, while future earnings expectations remain stable, resulting in an unchanged consensus price target of $23.57.
What's in the News
- Evolus updated 2025 earnings guidance, projecting total net revenues between $295–$305 million (11%–15% growth over 2024) and increasing Evolysse injectable HA gels' revenue contribution to 10%–12%.
- An independent head-to-head trial published in JAMA Dermatology found Jeuveau® outperformed competitors with faster onset, strongest peak effect, and longer duration versus Botox®; Jeuveau® now holds over 14% U.S. market share.
- Evolus partnered with Symatese to distribute Nuceiva (botulinum toxin type A) in France; clinical data and key opinion leaders reinforce Nuceiva's efficacy and millennial appeal in the evolving European aesthetics market.
- CFO Sandra Beaver resigned (effective June 13, 2025) for a new position; departure was not due to disagreements, and a search for her successor is underway with finance team oversight during transition.
- U.S. pivotal study results for Evolysse Form and Evolysse Smooth HA gels were published, demonstrating statistical superiority, long-term safety, and effectiveness for treating moderate to severe facial wrinkles.
Valuation Changes
Summary of Valuation Changes for Evolus
- The Consensus Analyst Price Target remained effectively unchanged, at $23.57.
- The Discount Rate for Evolus has risen from 6.40% to 6.78%.
- The Future P/E for Evolus remained effectively unchanged, moving only marginally from 27.35x to 27.64x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.